CareDx (CDNA) is a Great Momentum Stock: Should You Buy?
Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Industry Outlook CareDx, BrightSpring and PACS
CareDx, BrightSpring and PACS have been highlighted in this Industry Outlook article.
CareDx, Inc. (CDNA) Q2 2026 Earnings Call Transcript
CareDx, Inc. (CDNA) Q2 2026 Earnings Call Transcript
CareDx (CDNA) Beats Q2 Earnings and Revenue Estimates
CareDx (CDNA) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.1 per share a year ago.
CareDx Q2 Earnings Call Highlights
CareDx NASDAQ: CDNA reported second-quarter 2026 revenue growth of 52% as the transplant diagnostics company expanded testing services, completed the sale of its lab products business and began integrating the recently acquired NavDx specialty oncology platform.
CareDx (CDNA) Earnings Expected to Grow: Should You Buy?
CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CareDx's Growth Prospects With Naveris Keep Me Bullish
CareDx has a transplant-testing franchise that taps into recurring surveillance demand and has deeper integration into transplant centers. I also think CDNA's AlloHeme gives them longer-term optionality in post-cell-therapy monitoring. More recently, CDNA sold Lab Products and purchased Naveris. These major strategic M&A deals mean CDNA now has a potential growth engine in oncology.
CareDx (CDNA) Moves 35.6% Higher: Will This Strength Last?
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CareDx Completes Naveris Acquisition and Expands Oncology Reach
CDNA closes its Naveris buyout, adding NavDx and expanding its precision diagnostics reach into high-growth specialty oncology.
CareDx: The Transplant Platform Is Becoming A Specialty Diagnostics Compounder
CareDx has transformed into a focused, high-acuity specialty diagnostics platform, emphasizing repeat testing, data-rich services, and workflow integration. Recent strategic actions—Lab Products divestiture, Naveris acquisition, and VANTx launch—sharpen CDNA's growth profile, recurring revenue, and margin potential. Q1 2026 marked a shift to operating leverage: 39% revenue growth, gross margin expansion to 71%, and positive net income, with strong guidance for 2026.
CareDx (CDNA) Moves 11.5% Higher: Will This Strength Last?
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CareDx Sharpens Precision Diagnostics Push With Naveris Deal, AlloHeme Plans
CareDx NASDAQ: CDNA executives outlined the company's strategy to focus on precision diagnostics, expand into minimal residual disease testing and improve profitability during a Goldman Sachs-hosted discussion.
